Advertisement

Topics

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency

08:30 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Innocrin Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of the oral, selective CYP17-lyase/androgen receptor (AR) inhibitor seviteronel for castration resistant prostate cancer (CRPC...

Other Sources for this Article

Innocrin Pharmaceuticals, Inc.
Charles Osborne, CFO, +1-919-200-6325

NEXT ARTICLE

More From BioPortfolio on "Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...